JP2019535836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535836A5 JP2019535836A5 JP2019548534A JP2019548534A JP2019535836A5 JP 2019535836 A5 JP2019535836 A5 JP 2019535836A5 JP 2019548534 A JP2019548534 A JP 2019548534A JP 2019548534 A JP2019548534 A JP 2019548534A JP 2019535836 A5 JP2019535836 A5 JP 2019535836A5
- Authority
- JP
- Japan
- Prior art keywords
- sepiapterin
- free base
- crystal form
- ray diffraction
- deficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022151886A JP2023002532A (ja) | 2016-11-29 | 2022-09-22 | セピプテリン及びその塩の多形 |
| JP2024087740A JP2024123011A (ja) | 2016-11-29 | 2024-05-30 | セピプテリン及びその塩の多形 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427686P | 2016-11-29 | 2016-11-29 | |
| US62/427,686 | 2016-11-29 | ||
| US201762546390P | 2017-08-16 | 2017-08-16 | |
| US62/546,390 | 2017-08-16 | ||
| PCT/US2017/063517 WO2018102315A1 (en) | 2016-11-29 | 2017-11-28 | Polymoprhs of sepiapterin and salts thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151886A Division JP2023002532A (ja) | 2016-11-29 | 2022-09-22 | セピプテリン及びその塩の多形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535836A JP2019535836A (ja) | 2019-12-12 |
| JP2019535836A5 true JP2019535836A5 (enExample) | 2021-01-14 |
| JP7148533B2 JP7148533B2 (ja) | 2022-10-05 |
Family
ID=62241930
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548534A Active JP7148533B2 (ja) | 2016-11-29 | 2017-11-28 | セピプテリン及びその塩の多形 |
| JP2022151886A Pending JP2023002532A (ja) | 2016-11-29 | 2022-09-22 | セピプテリン及びその塩の多形 |
| JP2024087740A Pending JP2024123011A (ja) | 2016-11-29 | 2024-05-30 | セピプテリン及びその塩の多形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022151886A Pending JP2023002532A (ja) | 2016-11-29 | 2022-09-22 | セピプテリン及びその塩の多形 |
| JP2024087740A Pending JP2024123011A (ja) | 2016-11-29 | 2024-05-30 | セピプテリン及びその塩の多形 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11072614B2 (enExample) |
| EP (1) | EP3548497A4 (enExample) |
| JP (3) | JP7148533B2 (enExample) |
| KR (3) | KR102561697B1 (enExample) |
| CN (2) | CN116903624A (enExample) |
| AU (3) | AU2017366879C1 (enExample) |
| BR (1) | BR122021026889A8 (enExample) |
| CA (1) | CA3043502A1 (enExample) |
| CO (1) | CO2019006018A2 (enExample) |
| IL (2) | IL266955B2 (enExample) |
| MA (1) | MA46973A (enExample) |
| MX (3) | MX386520B (enExample) |
| NZ (1) | NZ753504A (enExample) |
| WO (1) | WO2018102315A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) * | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
| AU2021209935A1 (en) | 2020-01-24 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating Parkinson's disease with sepiapterin |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| WO2023055923A1 (en) | 2021-09-29 | 2023-04-06 | Ptc Therapeutics, Inc. | Pharmaceutical composition of sepiapterin |
| WO2024249602A2 (en) * | 2023-05-30 | 2024-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target |
| CN117205164B (zh) * | 2023-09-30 | 2024-07-26 | 山东新时代药业有限公司 | 一种盐酸沙丙蝶呤片剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| ES2177654T3 (es) | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| EP0854934A4 (en) | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| WO2005041975A1 (en) | 2003-10-31 | 2005-05-12 | Altana Pharma Ag | Use of bh4 for the treatment of respiratory diseases |
| JP2007536210A (ja) | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| HUE029533T2 (en) | 2003-11-17 | 2017-03-28 | Biomarin Pharm Inc | Treatment of phenylketonuria with BH4 |
| AU2004290692A1 (en) | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| EP2436379A1 (en) | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
| EP1819340A2 (en) * | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| DK3461503T3 (da) * | 2007-04-11 | 2022-02-14 | Biomarin Pharm Inc | Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder |
| NZ588379A (en) * | 2008-03-10 | 2012-07-27 | Takeda Pharmaceutical | Crystal of benzimidazole compound |
| ES2736730T3 (es) | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| US9884909B2 (en) * | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP2680848A4 (en) | 2011-03-01 | 2014-11-05 | Rubicon Res Private Ltd | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) * | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| AU2017286544B2 (en) | 2016-06-13 | 2022-10-20 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| JP2019527242A (ja) | 2016-07-29 | 2019-09-26 | ディファーマ エッセ．ア． | サプロプテリンジヒドロクロリドを含む医薬組成物キット |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| TWI765936B (zh) | 2016-11-29 | 2022-06-01 | 美商東京威力科創Ｆｓｉ股份有限公司 | 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
-
2017
- 2017-11-28 IL IL266955A patent/IL266955B2/en unknown
- 2017-11-28 AU AU2017366879A patent/AU2017366879C1/en active Active
- 2017-11-28 KR KR1020197015403A patent/KR102561697B1/ko active Active
- 2017-11-28 MA MA046973A patent/MA46973A/fr unknown
- 2017-11-28 CN CN202310843616.4A patent/CN116903624A/zh active Pending
- 2017-11-28 KR KR1020237025450A patent/KR102789662B1/ko active Active
- 2017-11-28 KR KR1020257010115A patent/KR20250051124A/ko active Pending
- 2017-11-28 EP EP17876202.7A patent/EP3548497A4/en active Pending
- 2017-11-28 WO PCT/US2017/063517 patent/WO2018102315A1/en not_active Ceased
- 2017-11-28 MX MX2019006206A patent/MX386520B/es unknown
- 2017-11-28 BR BR122021026889A patent/BR122021026889A8/pt not_active Application Discontinuation
- 2017-11-28 CA CA3043502A patent/CA3043502A1/en active Pending
- 2017-11-28 NZ NZ753504A patent/NZ753504A/en unknown
- 2017-11-28 US US16/464,771 patent/US11072614B2/en active Active
- 2017-11-28 CN CN201780084821.XA patent/CN110248948B/zh active Active
- 2017-11-28 JP JP2019548534A patent/JP7148533B2/ja active Active
- 2017-11-28 IL IL301470A patent/IL301470A/en unknown
-
2019
- 2019-05-28 MX MX2021011683A patent/MX2021011683A/es unknown
- 2019-05-28 MX MX2021011676A patent/MX2021011676A/es unknown
- 2019-06-10 CO CONC2019/0006018A patent/CO2019006018A2/es unknown
-
2021
- 2021-06-09 US US17/342,910 patent/US11773097B2/en active Active
-
2022
- 2022-05-23 AU AU2022203481A patent/AU2022203481B2/en active Active
- 2022-09-22 JP JP2022151886A patent/JP2023002532A/ja active Pending
-
2023
- 2023-08-21 US US18/236,095 patent/US12269829B2/en active Active
-
2024
- 2024-01-18 AU AU2024200344A patent/AU2024200344B2/en active Active
- 2024-05-30 JP JP2024087740A patent/JP2024123011A/ja active Pending
-
2025
- 2025-01-15 US US19/021,475 patent/US20250230164A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535836A5 (enExample) | ||
| JP2020500931A5 (enExample) | ||
| JP5129132B2 (ja) | ４−メチル−ｎ−［３−（４−メチル−イミダゾル−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの塩 | |
| JP2011513485A5 (enExample) | ||
| CN1367786A (zh) | 西酞普兰的制备方法 | |
| PL198385B1 (pl) | Sposób wytwarzania 5-cyjanoftalidu | |
| SK8962001A3 (en) | Method for the preparation of 5-cyanophthalide | |
| CA2848631A1 (en) | Rilpivirine hydrochloride | |
| JP2009531313A5 (enExample) | ||
| CN107635969A (zh) | 恩杂鲁胺结晶形式的制造方法 | |
| JP2018520188A (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 | |
| CN110627791A (zh) | 一种fascaplysin衍生物及制备方法 | |
| JP2007131628A (ja) | レボフロキサシンおよびその形態の調製 | |
| JP5640017B2 (ja) | イバブラジン硫酸塩及びそのｉ型結晶の製造方法 | |
| CN101768150B (zh) | 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸晶型及其制备方法 | |
| CN103232380A (zh) | 一种泊马度胺关键中间体的制备方法 | |
| WO2015199167A1 (ja) | 置換されたスピロピリド［１，２－ａ］ピラジン誘導体の製造方法および中間体 | |
| CN104829590B (zh) | 一种纯化曲格列汀的方法 | |
| JP2009149600A (ja) | エスシタロプラムの製造方法 | |
| JP5285914B2 (ja) | 有機化合物 | |
| TW201829420A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
| EP2358369A1 (en) | Process for the preparation of substantially optically pure repaglinide and precursors thereof | |
| WO2019037161A1 (zh) | 一种合成氯法齐明关键中间体n-(4-氯苯基)-1，2-苯二胺的方法 | |
| WO2013150544A2 (en) | Ivabradine hydrochloride solid dispersion | |
| CN102250063B (zh) | 甲磺酸伊马替尼的晶型及其制备方法 |